Intervet Dieter Luetticken Award

Intervet’s award to reduce the number of animals used in testing for development and production of animal veterinary medicines

Intervet offers the Dieter Lütticken award to promote scientists or life science research institutions working in research areas that serve the 3R-concept i.e. reducing, refining or replacing the use of animals in testing for development and production of veterinary medicines. The total funding for the award is 20,000 Euro. Application deadline is November 15, 2007. 
 
This international award, established in 2004, will be given to scientists or public institutions that have delivered excellent contributions to the 3R's for the development and production of veterinary medicinal products. The award’s scope covers in vitro models used in R&D which replace animal testing for licensing purposes as well as studies avoiding the use of animals in efficacy, safety and quality testing in the production of biologicals and pharmaceuticals for animals.

Intervet would like to see the scope interpreted as broadly as possible. It can cover, for example, residue testing, new toxicological methods, challenging test replacements, epidemiological studies focusing on the correlation of field data and protection of animals by vaccination, new epitope identification, genomics, proteomics, alternatives to production methods using animal by-products or animals.

A jury panel composed of experts from public institutions of the animal health/animal testing sector and Intervet representatives will look for possible candidates and will make the final selection. Intervet also welcomes submissions from all life-science research institutions. Commercial organizations are excluded. Candidates should give full contact details, co-operations partners, an executive summary of the studies and an argumentation why they should be taken into consideration, a publications list related to the study and a selection of copies of those publications which give a good overview of the work. For application forms please contact Intervet Global Communications & Public Affairs, Boxmeer the Netherlands (communications@intervet.com). This year’s deadline is November 15, 2007.

------

Note for the editor
Intervet, a business unit of Akzo Nobel, based in Boxmeer, the Netherlands, with sales of EUR 1,125 million in 2006, is dedicated to research and development, production and marketing of innovative animal health products. Intervet's product range for use in livestock, companion animals, poultry and fish includes vaccines, antiparasitics, anti-infectives, endocrine products, other pharmaceutical specialties. Intervet operates globally with its own marketing organizations. The company currently employs around 5,300 people.
Internet: www.intervet.com

Akzo Nobel is a Fortune Global 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the second quarter will be published on July 24, 2007.

Internet: www.akzonobel.com

Not for publication – for more information
Sabine Schueller                        Tel:  +31 (0)485 587085
Communications & Public Affairs  Fax: +31 (0)485 585392
Intervet International bv             communications@intervet.com